Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Given Consensus Rating of “Moderate Buy” by Brokerages

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Rating) (TSE:AUP) has earned a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $12.33.

Several analysts have recently issued reports on the company. SVB Leerink reduced their price objective on Aurinia Pharmaceuticals from $17.00 to $12.00 and set an “outperform” rating on the stock in a research report on Friday, November 4th. HC Wainwright decreased their price target on shares of Aurinia Pharmaceuticals from $26.00 to $14.00 and set a “buy” rating on the stock in a research note on Monday, November 7th. Royal Bank of Canada reissued an “outperform” rating and set a $11.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Thursday, February 23rd. Finally, Oppenheimer cut shares of Aurinia Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Friday, November 4th.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. Raymond James & Associates acquired a new position in Aurinia Pharmaceuticals in the first quarter valued at $140,000. BlackRock Inc. grew its holdings in shares of Aurinia Pharmaceuticals by 0.4% during the 1st quarter. BlackRock Inc. now owns 1,827,416 shares of the biotechnology company’s stock worth $22,624,000 after purchasing an additional 6,677 shares during the period. Great West Life Assurance Co. Can increased its position in Aurinia Pharmaceuticals by 22.3% during the 1st quarter. Great West Life Assurance Co. Can now owns 6,533 shares of the biotechnology company’s stock worth $86,000 after purchasing an additional 1,192 shares in the last quarter. Vontobel Holding Ltd. raised its holdings in Aurinia Pharmaceuticals by 69.9% in the first quarter. Vontobel Holding Ltd. now owns 26,000 shares of the biotechnology company’s stock valued at $322,000 after buying an additional 10,700 shares during the period. Finally, Vanguard Group Inc. lifted its position in Aurinia Pharmaceuticals by 26.3% during the first quarter. Vanguard Group Inc. now owns 530,059 shares of the biotechnology company’s stock valued at $6,562,000 after buying an additional 110,354 shares in the last quarter. Institutional investors and hedge funds own 40.36% of the company’s stock.

Aurinia Pharmaceuticals Trading Down 1.1 %

Shares of NASDAQ AUPH opened at $8.99 on Thursday. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -10.83 and a beta of 1.16. The company’s 50-day moving average price is $7.71 and its 200 day moving average price is $6.95. Aurinia Pharmaceuticals has a 52 week low of $4.07 and a 52 week high of $13.41.

Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Rating) (TSE:AUP) last released its quarterly earnings results on Tuesday, February 28th. The biotechnology company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.08. Aurinia Pharmaceuticals had a negative net margin of 89.50% and a negative return on equity of 26.03%. The business had revenue of $28.40 million for the quarter, compared to analyst estimates of $28.82 million. During the same period in the prior year, the business earned ($0.25) earnings per share. The company’s quarterly revenue was up 21.4% on a year-over-year basis. As a group, research analysts expect that Aurinia Pharmaceuticals will post -0.85 earnings per share for the current year.

Aurinia Pharmaceuticals Company Profile

(Get Rating)

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.